Hostname: page-component-76fb5796d-zzh7m Total loading time: 0 Render date: 2024-04-25T12:14:15.802Z Has data issue: false hasContentIssue false

P-144 - Duloxetine in Somatic Gastric Pain

Published online by Cambridge University Press:  15 April 2020

M. Preve
Affiliation:
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology
C. Nisita
Affiliation:
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology
M. Bellini
Affiliation:
Gastrointestinal Unit, Department of Gastroenterology, University of Pisa, Pisa, Italy
L. Di Paolo
Affiliation:
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology
S. Pini
Affiliation:
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology
L. Dell’osso
Affiliation:
Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Panic disorder is the most common anxiety disorder and panic attacks are the most common expression of panic disorder. Panic attacks are characterized with sudden attacks of anxiety with numerous somatic symptoms, such as palpitations, tachycardia, tachypnea, nausea, vertigo (cardiovascular, gastro-enterological, respiratory and neurootological symptoms). Sometimes in clinical practice panic disorder show itself with isolated gastroenteric or cardiovascular symptoms, that request other clinical visit and after psychiatric intervention. The SSRIs are preferred treatment for anxiety disorders and in particular panic disorder. However these drugs may cause some adverse effects such as sexual disfunction (Serretti A et al., 2011), increased bodyweight (Serretti A et al., 2010), abnormal bleending (Andrade C et al., 2010) and others, that may be problematic for some patients.We hereby describe the case of G.V., a 29-year-old Caucasican young woman affected by panic disorder with agoraphobia, referred to our clinic for of the re-occurrence of panic gastroenteric symptoms. With SSRIs the patients feelt an improvement in every anxiety symptoms and panic attacks, but not in the gastric somatic concern, then we decided to enter duloxetine. After six months treatment the patient presented complete remission of gastric sypmtoms and panic related symptoms, and suspended every tree different gastric treatment. Others author like Simon NM et al., hypothesized and confirm the duloxetine a serotonin-norepinephrine inhibitor (SNRI) that has greater initial noradrenergic effects than venlafaxine, would have broad efficacy for individuals with panic disorder.

Our case report underlines the possibility of tailored therapeutic strategies for gastroenteric expression of panic disorder.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.